1. Home
  2. DLTH vs IMUX Comparison

DLTH vs IMUX Comparison

Compare DLTH & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Duluth Holdings Inc. Class B

DLTH

Duluth Holdings Inc. Class B

HOLD

Current Price

$3.52

Market Cap

138.0M

ML Signal

HOLD

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$14.55

Market Cap

152.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DLTH
IMUX
Founded
1989
2016
Country
United States
United States
Employees
N/A
66
Industry
Clothing/Shoe/Accessory Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
138.0M
152.6M
IPO Year
2015
2013

Fundamental Metrics

Financial Performance
Metric
DLTH
IMUX
Price
$3.52
$14.55
Analyst Decision
Buy
Strong Buy
Analyst Count
1
6
Target Price
$7.00
$36.00
AVG Volume (30 Days)
63.3K
252.6K
Earning Date
06-04-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
64.12
38.00
EPS
N/A
N/A
Revenue
$565,184,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2.80
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.82
$0.51
52 Week High
$4.66
$15.77

Technical Indicators

Market Signals
Indicator
DLTH
IMUX
Relative Strength Index (RSI) 55.67 80.56
Support Level $3.39 $0.74
Resistance Level $3.63 N/A
Average True Range (ATR) 0.22 1.20
MACD 0.02 -0.04
Stochastic Oscillator 75.15 83.06

Price Performance

Historical Comparison
DLTH
IMUX

About DLTH Duluth Holdings Inc. Class B

Duluth Holdings Inc is an apparel brand in the United States. The company offers shirts, pants, and casual wear for men and women under brands like Alaskan Hardgear, Armachillo, Ballroom, Cab Commander, Crouch Gusset, Dry on the Fly, Duluth Trading Co, Duluthflex, Fire Hose, Longtail T, No Polo Shirt, No Yank, Wild Boar, and others. The Company's revenue consists of the sale of apparel, footwear, and hard goods. The company operates in a single operating segment.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Share on Social Networks: